Gary McCord has over 30 years of sales, marketing, and executive management experience in the early-stage medical device industry. Gary is currently Chief Commercial Officer at Vantis Vascular, another early-stage company developing therapeutic delivery systems to improve heart and vascular procedures.
Prior to Vantis Vascular, Gary was Chief Commercial Officer at Venclose Vascular which was acquired by Becton Dickson. He has held leadership positions with TriReme Medical, Sapheon, Cardiovascular Systems, Inc., Fox Hollow, X Technologies, Interventional Technologies, Heart Technologies, Pilot Cardiovascular Systems, and Ventritex—all privately held, entrepreneurial cardiovascular enterprises later acquired by companies such as Abbott, Bard, Medtronic, Boston Scientific, Guidant, and St. Jude Medical.
Gary holds a Bachelor of Arts in Communications from the University of Missouri, Columbia, and currently serves on several med-tech boards.